ArticleThe Journal of biological chemistry2019
Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
Open access · hybridAbstract read
In one paragraph
Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Senogenic-senolytic treatment strategies enhance tumor control and can improve survival in murine cancer models: a systematic review.BMC cancer · 2026Pooled it
- BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.International journal of molecular sciences · 2026Review
- Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery.Acta pharmaceutica Sinica. B · 2025Review
- Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state.Cell death and differentiation · 2025Article
- Cellular senescence in the tumor with a bone niche microenvironment: friend or foe?Clinical and experimental medicine · 2025Review
- Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment.Cancer communications (London, England) · 2024Review
- Modulation of tumor plasticity by senescent cells: Deciphering basic mechanisms and survival pathways to unravel therapeutic options.Genetics and molecular biology · 2024Article
- Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer.Molecular cancer therapeutics · 2023Review
- Could senescence phenotypes strike the balance to promote tumor dormancy?Cancer metastasis reviews · 2023Review
- Cellular senescence: a double-edged sword in cancer therapy.Frontiers in oncology · 2023Review
- A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Integration of TE Induces Cancer Specific Alternative Splicing Events.International journal of molecular sciences · 2022Review
- Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer.International journal of molecular sciences · 2022Article
- From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs.Open biology · 2022Review
- Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.Journal of hematology & oncology · 2022Review
- Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia.Nature communications · 2022Article
- Review
- SLC25A1-associated prognostic signature predicts poor survival in acute myeloid leukemia patients.Frontiers in genetics · 2022Article
- The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.Nature reviews. Cancer · 2022Review
- Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Sylvia S GayleFrom the Departments of Pharmacology.
Jennifer M SahniFrom the Departments of Pharmacology.
Bryan M WebbFrom the Departments of Pharmacology.
Kristen L Weber-BonkFrom the Departments of Pharmacology.
Melyssa S ShivelyFrom the Departments of Pharmacology.
Raffaella SpinaNeurological Surgery, and.
Eli E BarNeurological Surgery, and.
Mathew K SummersDepartment of Radiation Oncology and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210.
Ruth A KeriFrom the Departments of Pharmacology, keri@case.edu.ORCID 0000-0002-1640-3088
Case Western Reserve University · USNeurological Surgery · USKema International (Netherlands) · NLThe Ohio State University · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MRESEARCH ONCOLOGY TRAINING GRANTT32CA059366 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 1993 to 2025
$5.5MNRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9MTargeting BET proteins in Triple Negative Breast CancerR01CA206505 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI KERI, RUTH A. · 2016 to 2020
$1.8MTargeting Brain Tumor Stem Cells In The Hypoxic MicroenvironmentR01CA187780 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI BAR, ELI E · 2015 to 2019
$1.8MMechanisms of Spindle Assembly Checkpoint SilencingR01GM108743 · NIGMS · OHIO STATE UNIVERSITY · PI SUMMERS, MATTHEW K · 2014 to 2017
$1.2MDissecting functional interplay of deubiquitinases and the cell cycle machineryR01GM112895 · NIGMS · OHIO STATE UNIVERSITY · PI SUMMERS, MATTHEW K · 2015 to 2018
$1.2MDefining the Super-Enhancer Landscape in Triple Negative Breast Cancer SubtypesF31CA224809 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI WEBB, BRYAN MONROE · 2017 to 2019
$147kIdentifying epigenetic drivers and their targets in aggressive breast and ovarian cancersF99CA212460 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI SAHNI, JENNIFER · 2016 to 2017
$68kEpigenetically Reversing Paclitaxel Resistance in Triple Negative Breast CancersF32CA210426 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GAYLE, SYLVIA SHABAYA · 2017 to 2017
$62kNCATS NIH HHS TL1 TR002549NCI NIH HHS F31 CA224809NCI NIH HHS F32 CA210426NCI NIH HHS F99 CA212460NCI NIH HHS R01 CA187780NCI NIH HHS R01 CA206505NCI NIH HHS T32 CA059366NIGMS NIH HHS R01 GM108743NIGMS NIH HHS R01 GM112895NIGMS NIH HHS T32 GM007250
Abstract
Inhibitors of bromodomain and extra-terminal proteins (BETi) suppress oncogenic gene expression and have been shown to be efficacious in many
Indexed as
ApoptosisCellular Senescencebcl-X ProteinBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorFemaleHumansNuclear ProteinsTranscription FactorsTriple Negative Breast NeoplasmsBCL2L1 protein, humanbcl-X ProteinBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsNuclear ProteinsTranscription FactorsapoptosisB-cell lymphoma 2 (Bcl-2) familyB-cell lymphoma-extra largeBCL2L1BCL-xLBET inhibitorbreast cancerbromodomain-containing protein 4 (BRD4)senescencesenolytic agent
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.